Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323 (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of Prof. Richard Chang. He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA.
Encouraged by the clinical results with TPA in China, Roger Strair MD, PhD, a leading oncologist at the University of Medicine and Dentistry at Rutgers University, obtained an investigator IND and successfully completed a Phase 1 study in patients, the majority of whom had relapsed/refractory AML. Rich Pharmaceuticals was encouraged by Dr. Strair to conduct a Phase 2 study in relapsed/refractory AML. A Phase 2 study is currently underway under the direction of Dr. Strair who is actively enrolling appropriate patients in this study. Since this study, UMDNJ has changed their name to Rutgers, Cancer Institute of New Jersey where Rich Pharmaceuticals plans on conduction P2 clinical trials.
Rich Pharmaceuticals is protected by an issued “use patent” that gives sole rights to the Company to use the intravenous administration of TPA for therapeutic purposes. Since TPA can only be administered for therapeutic purposes by this route, this patent provides complete protection for the use of TPA for any other use.
Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials
Rich Pharmaceuticals Announces Institutional Review Board Submission
Rich Pharmaceuticals Announces Clinical Site in Thailand